Interim Analysis of Randomized Double-Blind Clinical Trial Using MRT in PTSD Thirty-six combat veterans (32 male, 4 female) with PTSD were included in the present RCT study. Two patients were excluded from analysis due to the premature reveal of the treatment code and withdrew from the trial. The study was designed with two treatment phases: 1) double-blind and 2) open-label. All patients were randomly assigned into one of the two study groups: Sham or MRT, and treated for two week during phase 1 followed by two more weeks of openlabel MRT trial. Clinical symptoms were evaluated by PCL-M scale at baseline, ends of week 1, week 2, and week 4. Figure attached below display the PCL-M mean score change from baseline following phase 1 and phase 2 treatments in both study groups. Analysis of covariance of PCL-M score shows significant difference between Sham and MRT after week 1 and week 2 double-blind trial (F1,31 = 4.6, p = 0.03) and no difference after week 4 open-label treatment (F1,31 = 0.01, p = 0.91). Average symptom reduction for both groups following the two-phase treatment is 65%. Two of 15 patients in the Sham group responded significantly in the first phase suggests some placebo effect. Since most patients remained on their existing medical treatment, the Sham response may reflect the effect of other treatment. These study results resemble the BTC clinical data well. Over 100 combat veterans with PTSD/TBI have been treated. The average PCL-M score reduction is 61%. PCL-M Score Sham MRT